Valuation: Nicox SA

Market Cap 2.67Cr 2.93Cr 2.47Cr 2.24Cr 4.2Cr 274.07Cr 4.4Cr 30Cr 12Cr 148.1Cr 11Cr 11Cr 469.13Cr P/E 2026 *
-5.5x
P/E 2027 * 13.8x
Enterprise Value 2.67Cr 2.93Cr 2.47Cr 2.24Cr 4.2Cr 274.07Cr 4.4Cr 30Cr 12Cr 148.1Cr 11Cr 11Cr 469.13Cr EV / Sales 2026 *
8.91x
EV / Sales 2027 * 2.67x
Free-Float
96.11%
Yield 2026 *
-
Yield 2027 * -
1 day-2.31%
1 week-5.17%
Current month-8.03%
1 month-7.41%
3 months-28.39%
6 months-28.29%
Current year-7.72%
1 week 0.28
Extreme 0.275
0.29
1 month 0.28
Extreme 0.275
0.32
Current year 0.28
Extreme 0.275
0.57
1 year 0.28
Extreme 0.275
0.57
3 years 0.14
Extreme 0.14
0.65
5 years 0.14
Extreme 0.14
3.14
10 years 0.14
Extreme 0.14
13.68
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2024
Director of Finance/CFO 58 01/01/2015
Corporate Officer/Principal - 01/01/2006
Director TitleAgeSince
Director/Board Member 55 08/04/2024
Chairman 64 16/07/2024
Director/Board Member - 16/07/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/01/22 Free

Chief Executive Officer

15,000 0.0348%
16/02/21 Exercice

Chief Executive Officer

10,000 0.0270%
01/02/20 Free

Chief Executive Officer

10,000 0.0300%
Change 5-day change 1-year change 3-year change Capi.($)
-2.31%-5.17%-12.56%-33.41% 3Cr
-2.29%-5.34%+28.73%+128.34% 1,23200Cr
-2.04%-5.78%+31.91%+78.34% 66TCr
-0.86%-3.71%+21.74%+105.02% 51TCr
-1.04%-1.80%+28.69%+68.01% 38TCr
-3.61%-9.62%+39.73%+30.53% 34TCr
-3.22%-5.20%+24.48%+51.30% 29TCr
-2.51%-4.49%-2.15%+29.67% 28TCr
-1.14%-6.05%+28.16%+65.35% 24TCr
-1.45%-0.85%+30.03%+120.72% 21TCr
Average -2.05%-2.59%+21.88%+64.39% 41TCr
Weighted average by Cap. -2.04%-2.67%+26.93%+87.80%

Financials

2026 *2027 *
Net sales 30L 32.93L 27.77L 25.12L 47.12L 31Cr 49.32L 3.36Cr 1.33Cr 17Cr 1.24Cr 1.21Cr 53Cr 1Cr 1.1Cr 92.57L 83.73L 1.57Cr 102.51Cr 1.64Cr 11Cr 4.44Cr 55Cr 4.12Cr 4.03Cr 175.46Cr
Net income -50L -54.88L -46.28L -41.87L -78.54L -51Cr -82.2L -5.59Cr -2.22Cr -28Cr -2.06Cr -2.02Cr -88Cr 20L 21.95L 18.51L 16.75L 31.42L 21Cr 32.88L 2.24Cr 88.77L 11Cr 82.36L 80.63L 35Cr
Net Debt - -
Projected Income Statement - Annual - Nicox SA
Logo Nicox SA
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Employees
5
Date Price Change Volume
19/26/19 €0.2750 -2.31% 1,51,106
18/26/18 €0.2815 -0.18% 2,28,494
17/26/17 €0.2820 -1.40% 81,691
16/26/16 €0.2860 -0.35% 42,063
13/26/13 €0.2870 -1.03% 82,753
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2750EUR
Average target price
1.000EUR
Spread / Average Target
+263.64%
  1. Stock Market
  2. Stocks
  3. ALCOX Stock